AMENDMENTS TO THE CLAIMS:

1. – 5. (Canceled)

6. (Currently Amended) A method of treating an autoimmune disorder or inflammatory disorder, or ameliorating one or more symptoms thereof, said method comprising administering to a subject in need thereof a therapeutically effective amount of one or more CD2 binding molecules and a therapeutically effective amount of one or more anti-angiogenic agents.

7. (Currently Amended) A method of treating an autoimmune disorder or inflammatory disorder, or ameliorating one or more symptoms thereof, said method comprising administering to a subject in need thereof a therapeutically effective amount of MEDI-507 or an antigen-binding fragment thereof and a therapeutically effective amount of one or more anti-angiogenic agents.

8. - 25. (Canceled)

26. (Currently Amended) The method of claim ~~2, 4 or~~ 6, wherein at least one CD2 binding molecule is an anti-CD2 antibody that immunospecifically binds to a CD2 polypeptide.

27. (Original) The method of claim 26, wherein the antibody is a monoclonal antibody.

28. (Original) The method of claim 27, wherein the monoclonal antibody is a human or humanized antibody.

29. (Currently Amended) The method of claim ~~2, 4 or~~ 6, wherein at least one CD2 binding molecule is a fusion protein that immunospecifically binds to a CD2 polypeptide.

30 (Original) The method of claim 29, wherein the fusion protein is LFA3TIP.

31. (Currently Amended) The method of claim ~~2, 4 or~~ 6, wherein the CD2 binding molecules are administered to said subject parenterally.

32. (Canceled)

33. (Currently Amended) The method of claim ~~1, 3, 5,~~ 7 ~~or 11~~, wherein MEDI-507 or an antigen-binding fragment thereof is administered to said subject parenterally.

34. (Currently Amended) The method of claim ~~2, 4 or~~ 6, wherein said effective amount of one or more CD2 binding molecules is a dose ranging from 0.5 ~~to100~~ to 100 μg/kg.

35. (Currently Amended) The method of claim ~~2, 4 or~~ 6, wherein said effective amount of one or more CD2 binding molecules is a unit dose of ~~0.1mg~~ 0.1 mg, 0.25 mg, 0.4 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 12 mg, 13 mg, 14 mg or 15 mg.

36. (Currently Amended) The method of claim ~~2, 4 or~~ 6, wherein said effective amount of one or more CD2 binding molecules is a unit dose of between 0.1 mg and 20 mg.

37. – 38. (Canceled)

39. (Currently Amended) The method of claim ~~2, 4 or~~ 6, wherein at least one CD2 binding molecule does not inhibit the interaction between a CD2 polypeptide and LFA-3.

40. (Currently Amended) The method of claim ~~1, 8, 9 or 10~~ 7, wherein said effective amount of MEDI-507 or an antigen-binding fragment thereof is a unit dose of 0.1 mg, 0.25 mg, 0.4 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, 10 mg, 11 mg, 12 mg, 13 mg, 14 mg or 15 mg.

41. – 61. (Canceled)

62. (Original) The method of claim 6 or 7, wherein at least one anti-angiogenic factor is angiostatin, a TNF-α antagonist, a VEGFR antagonist, an RGD containing peptide, or endostatin.

63. (Currently Amended) The method of claim 62, wherein the TNF-α antagonist is ~~ENBREL~~ etanercept or ~~REMICADE~~ infliximab.

64. – 65. (Canceled)

66. (Currently Amended) The method of ~~any one of claims 1-3 and 6-11~~ claim 6 or 7, wherein the autoimmune disorder is rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Reiter's Syndome, psorasis, or lupus erythematosus.

67. (Withdrawn) The method of any one of claims 1-3 and 6-11, wherein the inflammatory disorder is asthma, encephalitis, inflammatory bowel disease, chronic obstructive pulmonary disease (COPD), arthritis, or an allergic disorder.

68. (Canceled)

69. (Currently Amended) The method of ~~any one of claims 1-11~~ claim 6 or 7, wherein the subject is a human.

70 - 71. (Canceled)

72. (New) The method of claim 6, wherein the method comprises monitoring the mean absolute lymphocyte count in said subject after administration of a dose of an effective amount of one or more CD2 binding molecules.

73. (New) The method of claim 7, wherein the method comprises monitoring the mean absolute lymphocyte count in said subject after administration of a dose of an effective amount of MEDI-507 or an antigen-binding fragment thereof.

74. (New) The method of claim 29, wherein the fusion protein comprises the extracellular domain of LFA-3 or a fragment thereof and the Fc domain or a fragment thereof of an immunoglobulin domain.

75. (New) The method of claim 63, wherein the subject is a human.